Congenital Glioblastoma with Distinct Clinical and Molecular Characteristics: Case Reports and a Literature Review

Masahiro Kameda, Yoshihiro Otani, Tomotsugu Ichikawa, Akira Shimada, Koichi Ichimura, Isao Date

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background The molecular diagnosis of brain tumors is important in classifying tumors and determining appropriate treatment. Congenital glioblastoma multiforme (GBM) is a rare tumor that occurs in infants, and the prognosis is poor. Approximately 60 patients diagnosed with congenital GBM have been reported. However, few reports have conducted molecular analyses of congenital GBM. Case Description We describe 2 congenital GBM patients treated in our hospital, and report results of immunohistochemistry, fluorescent in situ hybridization (FISH), direct sequencing, and methylation analyses. Surgery was performed on both patients at 2 months old, and the cases were diagnosed as glioblastoma. Immunohistochemical staining, FISH, and direct sequencing were positive for glial fibrillary acidic protein and ATRX, partially positive for p53, showed no alteration of isocitrate dehydrogenase 1 R132H, H3F3A, HIST1H3B, and BRAF, and indicated no codeletion of 1p and 19q. Methylation analysis of 1 patient identified copy number aberrations of 4 genes: deletions of CDK6 and CDKN2A/B, and a fusion of MET. One patient received chemotherapy consisting of ranimustine, interferon-beta, carboplatin, and etoposide, whereas the other patient received chemotherapy with the modified Children's Cancer Group study-9921 protocol. Residual tumors in both patients were decreased, and they achieved 18-year- and 9-month progression-free survival, respectively. In addition, we reviewed 65 previously reported congenital GBM patients, and found they have better prognosis than pediatric and adult GBM, and long-term survival can be expected. Conclusions Congenital GBM demonstrates clinical and molecular characteristics that are different from those of pediatric or adult GBM.

Original languageEnglish
Pages (from-to)817.e5-817.e14
JournalWorld Neurosurgery
Volume101
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Glioblastoma
Fluorescence In Situ Hybridization
Methylation
Pediatrics
Isocitrate Dehydrogenase
Drug Therapy
Neoplasms
Interferon-beta
Carboplatin
Glial Fibrillary Acidic Protein
Gene Deletion
Residual Neoplasm
Etoposide
Brain Neoplasms
Disease-Free Survival
Immunohistochemistry
Staining and Labeling
Survival

Keywords

  • Congenital glioblastoma
  • Methylation
  • Pathologic findings
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Congenital Glioblastoma with Distinct Clinical and Molecular Characteristics : Case Reports and a Literature Review. / Kameda, Masahiro; Otani, Yoshihiro; Ichikawa, Tomotsugu; Shimada, Akira; Ichimura, Koichi; Date, Isao.

In: World Neurosurgery, Vol. 101, 01.05.2017, p. 817.e5-817.e14.

Research output: Contribution to journalArticle

@article{28c5e7375486406590161d6598c1af0d,
title = "Congenital Glioblastoma with Distinct Clinical and Molecular Characteristics: Case Reports and a Literature Review",
abstract = "Background The molecular diagnosis of brain tumors is important in classifying tumors and determining appropriate treatment. Congenital glioblastoma multiforme (GBM) is a rare tumor that occurs in infants, and the prognosis is poor. Approximately 60 patients diagnosed with congenital GBM have been reported. However, few reports have conducted molecular analyses of congenital GBM. Case Description We describe 2 congenital GBM patients treated in our hospital, and report results of immunohistochemistry, fluorescent in situ hybridization (FISH), direct sequencing, and methylation analyses. Surgery was performed on both patients at 2 months old, and the cases were diagnosed as glioblastoma. Immunohistochemical staining, FISH, and direct sequencing were positive for glial fibrillary acidic protein and ATRX, partially positive for p53, showed no alteration of isocitrate dehydrogenase 1 R132H, H3F3A, HIST1H3B, and BRAF, and indicated no codeletion of 1p and 19q. Methylation analysis of 1 patient identified copy number aberrations of 4 genes: deletions of CDK6 and CDKN2A/B, and a fusion of MET. One patient received chemotherapy consisting of ranimustine, interferon-beta, carboplatin, and etoposide, whereas the other patient received chemotherapy with the modified Children's Cancer Group study-9921 protocol. Residual tumors in both patients were decreased, and they achieved 18-year- and 9-month progression-free survival, respectively. In addition, we reviewed 65 previously reported congenital GBM patients, and found they have better prognosis than pediatric and adult GBM, and long-term survival can be expected. Conclusions Congenital GBM demonstrates clinical and molecular characteristics that are different from those of pediatric or adult GBM.",
keywords = "Congenital glioblastoma, Methylation, Pathologic findings, Prognosis, Treatment",
author = "Masahiro Kameda and Yoshihiro Otani and Tomotsugu Ichikawa and Akira Shimada and Koichi Ichimura and Isao Date",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.wneu.2017.02.026",
language = "English",
volume = "101",
pages = "817.e5--817.e14",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Congenital Glioblastoma with Distinct Clinical and Molecular Characteristics

T2 - Case Reports and a Literature Review

AU - Kameda, Masahiro

AU - Otani, Yoshihiro

AU - Ichikawa, Tomotsugu

AU - Shimada, Akira

AU - Ichimura, Koichi

AU - Date, Isao

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background The molecular diagnosis of brain tumors is important in classifying tumors and determining appropriate treatment. Congenital glioblastoma multiforme (GBM) is a rare tumor that occurs in infants, and the prognosis is poor. Approximately 60 patients diagnosed with congenital GBM have been reported. However, few reports have conducted molecular analyses of congenital GBM. Case Description We describe 2 congenital GBM patients treated in our hospital, and report results of immunohistochemistry, fluorescent in situ hybridization (FISH), direct sequencing, and methylation analyses. Surgery was performed on both patients at 2 months old, and the cases were diagnosed as glioblastoma. Immunohistochemical staining, FISH, and direct sequencing were positive for glial fibrillary acidic protein and ATRX, partially positive for p53, showed no alteration of isocitrate dehydrogenase 1 R132H, H3F3A, HIST1H3B, and BRAF, and indicated no codeletion of 1p and 19q. Methylation analysis of 1 patient identified copy number aberrations of 4 genes: deletions of CDK6 and CDKN2A/B, and a fusion of MET. One patient received chemotherapy consisting of ranimustine, interferon-beta, carboplatin, and etoposide, whereas the other patient received chemotherapy with the modified Children's Cancer Group study-9921 protocol. Residual tumors in both patients were decreased, and they achieved 18-year- and 9-month progression-free survival, respectively. In addition, we reviewed 65 previously reported congenital GBM patients, and found they have better prognosis than pediatric and adult GBM, and long-term survival can be expected. Conclusions Congenital GBM demonstrates clinical and molecular characteristics that are different from those of pediatric or adult GBM.

AB - Background The molecular diagnosis of brain tumors is important in classifying tumors and determining appropriate treatment. Congenital glioblastoma multiforme (GBM) is a rare tumor that occurs in infants, and the prognosis is poor. Approximately 60 patients diagnosed with congenital GBM have been reported. However, few reports have conducted molecular analyses of congenital GBM. Case Description We describe 2 congenital GBM patients treated in our hospital, and report results of immunohistochemistry, fluorescent in situ hybridization (FISH), direct sequencing, and methylation analyses. Surgery was performed on both patients at 2 months old, and the cases were diagnosed as glioblastoma. Immunohistochemical staining, FISH, and direct sequencing were positive for glial fibrillary acidic protein and ATRX, partially positive for p53, showed no alteration of isocitrate dehydrogenase 1 R132H, H3F3A, HIST1H3B, and BRAF, and indicated no codeletion of 1p and 19q. Methylation analysis of 1 patient identified copy number aberrations of 4 genes: deletions of CDK6 and CDKN2A/B, and a fusion of MET. One patient received chemotherapy consisting of ranimustine, interferon-beta, carboplatin, and etoposide, whereas the other patient received chemotherapy with the modified Children's Cancer Group study-9921 protocol. Residual tumors in both patients were decreased, and they achieved 18-year- and 9-month progression-free survival, respectively. In addition, we reviewed 65 previously reported congenital GBM patients, and found they have better prognosis than pediatric and adult GBM, and long-term survival can be expected. Conclusions Congenital GBM demonstrates clinical and molecular characteristics that are different from those of pediatric or adult GBM.

KW - Congenital glioblastoma

KW - Methylation

KW - Pathologic findings

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85016047755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016047755&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2017.02.026

DO - 10.1016/j.wneu.2017.02.026

M3 - Article

C2 - 28214639

AN - SCOPUS:85016047755

VL - 101

SP - 817.e5-817.e14

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -